118
Views
4
CrossRef citations to date
0
Altmetric
Review

Current and emerging treatment options for vernal keratoconjunctivitis

, , , , , & show all
Pages 343-353 | Received 19 Jan 2017, Accepted 24 Feb 2017, Published online: 07 Mar 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Chintan Malhotra, Himanshi Singh, Arun Kumar Jain, Amit Gupta & Jagat Ram. (2022) Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus. Ocular Immunology and Inflammation 30:5, pages 1083-1091.
Read now
Marcella Nebbioso, Ludovico Alisi, Francesca Giovannetti, Marta Armentano & Alessandro Lambiase. (2019) Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy . Clinical Ophthalmology 13, pages 1147-1155.
Read now

Articles from other publishers (2)

Asim Ali, Leonard Bielory, Stephanie Dotchin, Patrick Hamel, Yi Ning J. Strube & Euna B. Koo. (2023) Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape. Survey of Ophthalmology.
Crossref
Marta Sacchetti, Rocco Plateroti, Alice Bruscolini, Rosalia Giustolisi & Marco Marenco. (2021) Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms. Life 11:10, pages 1012.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.